Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
HBM Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
HBM Partners

HBM Partners

Operating

HBM Partners AG: A private equity firm investing in emerging bio-pharma and healthcare companies.

Location
Zug, Zug, CH
Founded
2001
Firm
Compare
Portfolio
Employees
Website

Investments

Fore Biotherapeutics
Fore Biotherapeutics

Total Raised

$166.5M

Rounds

9

Series D$75MAugust 2023
Convertible NoteOctober 2022
Series CSeptember 2021
Upstream Bio
Upstream Bio

Total Raised

$408M

Rounds

4

Series B$200MJune 2023
Series A$8MFebruary 2023
Antiva Biosciences
Antiva Biosciences

Total Raised

$140.3M

Rounds

9

Series E$53MApril 2023
Shape Memory Medical
Shape Memory Medical

Total Raised

$13.6M

Rounds

8

Convertible Note$600kApril 2023
Genalyte
Genalyte

Total Raised

$154.8M

Rounds

5

Series C$13MMarch 2023
Dren Bio
Dren Bio

Total Raised

$130.1M

Rounds

4

Series B$65MJune 2022
Vascular Dynamics
Vascular Dynamics

Total Raised

$105.1M

Rounds

10

Series DMay 2022
Neuron23
Neuron23

Total Raised

$213.5M

Rounds

4

Series C$100MMarch 2022
Series B$80MDecember 2020
Karius
Karius

Total Raised

$254M

Rounds

6

Series BMarch 2022
Numab
Numab

Total Raised

$122M

Rounds

3

Series C$100MMay 2021
iTeos Therapeutics
iTeos Therapeutics
Public

Total Raised

$242.7M

Rounds

9

Series B$125MApril 2020
Series B$75MJune 2018
Iconic Therapeutics
Iconic Therapeutics
Acquired

Total Raised

$82.8M

Rounds

12

Series A$4.1MJune 2018
Gynesonics
Gynesonics
Public

Total Raised

$401.8M

Rounds

16

Private Equity$75MJanuary 2018
Series Unknown$43MJuly 2015
Series B$28.4MJuly 2014
Series D$21MFebruary 2013
Hookipa Pharma
Hookipa Pharma
Public

Total Raised

$284.8M

Rounds

10

Series C$60MDecember 2017
Odyssey Thera
Odyssey Thera
Public

Total Raised

$6.3M

Rounds

2

Series Unknown$2.8MFebruary 2013
AGY Therapeutics
AGY Therapeutics

Total Raised

$22M

Rounds

2

Series C$9MAugust 2004
Bio Green Med Solution
Bio Green Med Solution
Public

Total Raised

$149.5M

Rounds

13

Series D$21.3MJanuary 2004